Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Liraglutide Effect in Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 60
- Registration Number
- NCT03856632
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT03757130
- Locations
- 🇺🇸
William D Summers MD LLC, Birmingham, Alabama, United States
🇺🇸QPS Miami Research Associates, South Miami, Florida, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Daily Liraglutide for Nicotine Dependence
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Rebecca Ashare
- Target Recruit Count
- 40
- Registration Number
- NCT03712098
- Locations
- 🇺🇸
Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT03707171
- Locations
- 🇨🇳
The third hospital affiliated to the Third Military Medical University, Chongqing, Chongqing, China
The Use of Liraglutide in Brain Death
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 50
- Registration Number
- NCT03672812
- Locations
- 🇧🇷
Hospital Santa Isabel, Blumenau, Santa Catarina, Brazil
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 150
- Registration Number
- NCT03671733
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Carla Greenbaum, MD
- Target Recruit Count
- 16
- Registration Number
- NCT03632759
- Locations
- 🇺🇸
Benaroya Research Institute, Seattle, Washington, United States
🇺🇸Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 30
- Registration Number
- NCT03619330
- Locations
- 🇸🇮
University Medical Center Ljubljana, Ljubljana, Slovenia
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 758
- Registration Number
- NCT03560336
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Yangsan, Korea, Republic of
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 51
- Registration Number
- NCT03555994
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.